CBIO logo

Crescent Biopharma, Inc.

CBIO
Healthcare|Biotechnology|US
$13.54
+0.60 (+4.64%)
DCF Value
$20.78
Tangible Book / Share
$5.35
Cash / Share
$5.62
Next Earnings Report
Mar 4, 2027
EPS est. -$0.70 · Revenue est. $357.1K
Financing Filings (last 12 months)
10
Shelf registrations / offering prospectuses — latest Jul 30, 2026 (424B3). Possible dilution.

Upcoming Data Readouts (2)

Oct 2028
Est. completion
P1P2Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
NCT07909031n=219
Feb 2029
Est. completion
P1P2Locally Advanced / Metastatic Solid Tumors
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
NCT07335497n=540

Recent Press Releases

Crescent Biopharma Announces Grants of Inducement Awards
Nov 3, 2026 · GlobeNewsWire
Crescent Biopharma to Present at November Investor Conferences
Nov 2, 2026 · GlobeNewsWire
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
Oct 15, 2026 · GlobeNewsWire
Crescent Biopharma Announces Grants of Inducement Awards
Oct 6, 2026 · GlobeNewsWire
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
Oct 5, 2026 · GlobeNewsWire
Crescent Biopharma Announces Grants of Inducement Awards
Sep 25, 2026 · GlobeNewsWire
Crescent Biopharma Announces Grants of Inducement Awards
Sep 9, 2026 · GlobeNewsWire
Crescent Biopharma to Present at September Investor Conferences
Sep 3, 2026 · GlobeNewsWire

SEC Filings (91)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 27, 2026SC 13GPassive 5%+ stakeDocumentIndex
Oct 15, 20268-KMaterial eventDocumentIndex
Sep 18, 2026S-8Employee stock planDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jul 31, 2026EFFECTDocumentIndex
Jul 30, 2026POS AMDocumentIndex
Jul 30, 2026424B3Offering prospectusDocumentIndex
Jul 30, 202610-QQuarterly reportDocumentIndex
Jul 30, 20268-KMaterial eventDocumentIndex
Jul 20, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Jul 15, 20268-KMaterial eventDocumentIndex
Jul 15, 2026424B5Offering prospectusDocumentIndex
Jul 14, 20268-KMaterial eventDocumentIndex
Jul 14, 2026424B5Offering prospectusDocumentIndex
Jul 10, 2026EFFECTDocumentIndex
Jul 1, 2026S-3Shelf registrationDocumentIndex
Jun 22, 2026424B3Offering prospectusDocumentIndex
Jun 22, 202610-Q/AQuarterly reportDocumentIndex
Jun 3, 20268-KMaterial eventDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 15, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 29, 2026424B3Offering prospectusDocumentIndex
Apr 29, 20268-KMaterial eventDocumentIndex
Apr 29, 202610-QQuarterly reportDocumentIndex
Apr 21, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 21, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 21, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 17, 2026424B3Offering prospectusDocumentIndex
Mar 3, 2026EFFECTDocumentIndex
Mar 3, 2026POS AMDocumentIndex
Feb 26, 2026424B3Offering prospectusDocumentIndex
Feb 26, 2026S-8Employee stock planDocumentIndex
Feb 26, 20268-KMaterial eventDocumentIndex
Feb 26, 202610-KAnnual reportDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13GPassive 5%+ stakeDocumentIndex
Feb 5, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 15, 2026EFFECTDocumentIndex
Jan 15, 2026424B3Offering prospectusDocumentIndex
Jan 7, 2026S-1IPO / offering registrationDocumentIndex